Trusselsvurderingen fra Center for Cybersikkerhed, der er rettet imod den danske sundhedssektor, udkom i juli. Vurderingen er, at truslen mod sundhedssektoren på 2 områder er MEGET HØJ, hvilket er det højeste niveau. Det drejer sig om henholdsvis Cyberspionage, hvor det vurderes, at fremmede stater har interesse i at stjæle forskningsdata og intellektuel ejendom fra sektoren. Det andet område er Cyberkriminalitet, hvor der er risiko for, at cyberkriminelle angreb kan forstyrre patientbehandlingen. Cyberangreb kan i yderste tilfælde føre til dødsfald, personskade og tab af tillid til sundhedsvæsenet blandt befolkningen
Dette øger kravene til IT-sikkerheden, beredskabsplaner og backup-systemer.
Trusselsvurderingen analyserer Cybertruslen mod sundhedssektoren som helhed. Sundhedssektoren inkluderer i denne vurdering derfor alt fra behandlingssteder, såsom hospitaler, lægepraksisser og tandlæger, til leverandører og producenter, der understøtter behandlingen. Herunder medicinalindustrien, Life Science-industrien, medicoindustrien og udbydere af IT-løsninger til behandlingssteder. Organisationer, der beskæftiger sig med sundhedsforskning, både privat og offentligt, samt myndigheder, der beskæftiger sig med sundhed, såsom Sundheds- og Ældreministeriet.
Konferencen Cybersikkerhed i sundhedssektoren vil fokusere på, hvordan disse trusler håndteres, så organisationerne, infrastrukturen og ydelserne i videst muligt omfang og hele tiden er tilgængelige og stabile, og den daglige patientbehandling ikke forstyrres.
Emner på konferencen:
Cybertruslen mod sundhedssektoren
Strategi for cyber- og informationssikkerhed på sundhedsområdet
Det svageste led i kæden – mennesket
PET’s erfaringer med awareness-træning
Persondataloven og sikker behandling af patientoplysninger
Implementering af nyt SCADA system
Konkrete erfaringer fra sundhedssektoren
.
Jeg glæder mig til at byde dig og dine kolleger velkommen på Cybersikkerhed i sundhedssektoren.
For mere information om program og deltagelse, kontakt:
Er du interesseret i at blive partner på konferencen, kontakt:
Conference organised by the Nordic Committee on Bioethics in collaboration with Centre for Legal Studies in Welfare and Market at the University of Copenhagen, 9 April 2019.
How are clinical innovations and unproven methods developed and introduced in western Nordic health-care systems? What is the legal and regulatory environment concerning unproven methods in medicine? What ethical principles should guide work on emerging treatments and experimentation in hospitals? In the upcoming NCBio-conference, these three questions will each be addressed in separate sessions.
Clinical innovation involves development of new techniques, methods, treatments and diagnostics for detecting, alleviating and curing diseases. By nature novel clinical methods and treatments are unproven when first developed. Through the centuries, medicine has advanced by trials and errors of physicians and researchers experimenting with treatments and methods. The failure of certain methods are inseparable from success of others, because a priori it is hard to know what works and what not. The scientific method is the preferred approach to develop cures and treatments, but many current medical practices were not developed by strict scientific testing or trials. Healthcare professionals may try unproven methods, for instance as a last resort in attempt to safe a life. Such unproven methods for clinics and health care, occur at the intersect of basic research and standard health-care and raise number of bioethical issues. Those include the following issues: Do patients have sufficient and equal access to the experimental methods? Are patients protected from harm when unproven methods are tested? Who should make decisions about when to experiment with a treatment? How can society and the health care system best simultaneously promote clinical innovation and protect patients?
The conference is open to all interested, including medical doctors, health committees in parliaments, senior civil servants and hospital administrators.
The first Tech & Law Breakfast this year focused on “Legal implications of Big Data in Danish Healthcare”.
Mette Hartlev and Katharina Eva Ó Cathaoir presented their research on personalized medicine in the welfare state.
How is “the personal” understood and established when genomic data are applied and exchanged in Danish health care?
Which collectivities—e.g. species, ethnicity, nation, health care services, and ultimately the welfare state— are implied in constituting “the personal”?